<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We used the Amersham radioimmunological method to measure plasma 1 alpha 25-dihydroxyvitamin D3 (<z:chebi fb="0" ids="17823">calcitriol</z:chebi>) levels in patients presenting with one of the following diseases: (i) non-<z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (39 cases); (ii) <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (43 cases) or in complete remission (15 cases) and (iii) <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoid <z:mpath ids='MPATH_336'>leukaemia</z:mpath> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (11 cases) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had <z:mpath ids='MPATH_458'>normal</z:mpath> metabolic functions </plain></SENT>
<SENT sid="2" pm="."><plain>Compared with our standard laboratory values (15-35 pg/ml), the results of these assays were related to the type of pathology or, in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath>, to the stage of the disease (p less than 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, the mean plasma <z:chebi fb="0" ids="17823">calcitriol</z:chebi> values differed according to the type of pathology (p less than 0.003) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> had a low level of <z:chebi fb="0" ids="17823">calcitriol</z:chebi> as compared with controls (p less than 0.05) and with patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> in complete remission (p less than 0.001) whose <z:chebi fb="0" ids="17823">calcitriol</z:chebi> levels were never low </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, there was no significant difference between controls and patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoid <z:mpath ids='MPATH_336'>leukaemia</z:mpath> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This study demonstrates the usefulness of plasma <z:chebi fb="0" ids="17823">calcitriol</z:chebi> assays in malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e> where low values in certain types of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> would incite to include <z:chebi fb="0" ids="17823">calcitriol</z:chebi> in therapeutic regimens </plain></SENT>
</text></document>